CLNN

Clene Inc.
CAPPED RATING

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Clene Inc. (CLNN) is rated C- (2.0/5) on Deltasharpe Prism, scored against Consumer Defensive sector peers. Its strongest pillar is Growth (B); its weakest is Value (F). The rating has held at C- for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
F
Factor Score 0.0 / 5.0
Growth
B
Factor Score 3.4 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.8
EV / EBITDA -3.4
Rev Growth YoY 233.3%
Gross Margin 70.1%
Price Return 3M 8.3%
Price Return 12M -55.0%
Catalyst Signal 0.00
Market Cap $63.5M
TTM Revenue $197.0K
Price / Sales 322.4
ROE N/A

Historical Factor Score Progression

Held C- for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 F (0.0) B (3.4) C (2.2) C- (2.0) C+ (2.6) C- (2.0)
2026-11-04 F (0.0) B (3.4) C (2.2) D (1.2) C+ (2.6) C- (1.9)
2026-10-28 F (0.0) B (3.3) C (2.3) D+ (1.8) C (2.4) C- (2.0)
2026-10-21 F (0.0) B (3.3) C (2.3) D (1.3) C (2.3) D+ (1.8)
2026-10-14 F (0.0) B (3.3) C (2.3) F (0.7) C (2.4) D+ (1.7)
Page 1 of 4